The company said its board appointed Jacob S. Leach, currently President and Chief Operating Officer, as President and Chief Executive Officer and as a director effective January 1, 2026, when Kevin R. Sayer resigns, also effective that date.

1. 01

   The company said its board appointed Jacob S. Leach, currently President and Chief Operating Officer, as President and Chief Executive Officer and as a director effective January 1, 2026, when Kevin R. Sayer resigns, also effective that date.

2. 02

   The company said Leach has served as interim principal executive officer in addition to his other duties since Sayer's medical leave of absence. It said this was previously reported in the 8-K filed on September 15, 2025.

3. 03

   The company said Leach's offer letter, entered into on December 19, 2025, provides for an annual base salary of $1,150,000 and an annual target bonus opportunity equal to 150% of base salary. It said the offer also includes restricted stock units with a fair value of $7,500,000, vesting annually over 3 years after the grant date, and performance stock units with a target fair value of $7,500,000.

4. 04

   The company said its board expects Sayer to return from his medical leave of absence in or about March 2026. It said Mark Foletta will remain interim Chairman of the Board until Sayer returns.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.